Encapsulation enhances stromal cell survival for safe neonatal therapy: a pilot study

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Neonatal Surgery

Background:

• Mesenchymal stromal cells (MSCs) show therapeutic potential for necrotizing enterocolitis (NEC).
• Clinical use of MSCs is limited by immune clearance and tumorigenic risks.
• Encapsulation may mitigate these risks by limiting systemic exposure.

Purpose of the Study:

• To evaluate the efficacy of a thread-reinforced encapsulation device (THRED) for preserving MSC viability and identity.
• To test the hypothesis that MSC encapsulation improves cell survival and maintains cell identity in vivo.

Main Methods:

• Luciferase-expressing MSCs were generated and administered intraperitoneally or encapsulated in THRED devices in mice.
• Cell viability was tracked using bioluminescence imaging over 8 days.
• Explanted cells were analyzed for viability and identity via flow cytometry and marker analysis.

Main Results:

• MSCs encapsulated in THRED demonstrated significantly higher viability on days 4 and 8 compared to free MSCs.
• Extracted cells from the THRED device remained viable and maintained characteristic stromal cell marker expression.
• Flow cytometry confirmed preserved cell viability and identity of explanted MSCs.

Conclusions:

• THRED encapsulation effectively preserves MSC viability and identity in vivo.
• This method offers a clinically practical approach for delivering MSC therapy in NEC.
• Encapsulation presents a feasible solution to barriers hindering neonatal MSC therapy.